Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Grows By 12.1%

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 2,320,000 shares, a growth of 12.1% from the December 15th total of 2,070,000 shares. Approximately 20.6% of the company’s shares are short sold. Based on an average daily volume of 412,100 shares, the short-interest ratio is presently 5.6 days.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. BMO Capital Markets assumed coverage on Jasper Therapeutics in a research note on Friday, December 6th. They set an “outperform” rating and a $63.00 target price on the stock. JMP Securities restated a “market outperform” rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a report on Monday, January 6th. Royal Bank of Canada cut their target price on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research note on Thursday, January 9th. Finally, HC Wainwright lowered their price objective on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating for the company in a report on Friday, January 10th. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $67.75.

Institutional Trading of Jasper Therapeutics

A number of hedge funds have recently made changes to their positions in JSPR. Braidwell LP purchased a new position in Jasper Therapeutics during the third quarter valued at $9,091,000. Ally Bridge Group NY LLC increased its holdings in shares of Jasper Therapeutics by 82.7% during the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after acquiring an additional 180,852 shares in the last quarter. Samsara BioCapital LLC raised its position in shares of Jasper Therapeutics by 11.4% in the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after purchasing an additional 59,642 shares during the last quarter. FMR LLC bought a new position in Jasper Therapeutics in the 3rd quarter worth about $722,000. Finally, Bank of New York Mellon Corp bought a new position in Jasper Therapeutics in the 2nd quarter worth about $740,000. 79.85% of the stock is owned by institutional investors.

Jasper Therapeutics Trading Up 3.2 %

JSPR traded up $0.17 during midday trading on Friday, reaching $5.51. The company’s stock had a trading volume of 720,615 shares, compared to its average volume of 549,720. Jasper Therapeutics has a 1 year low of $5.25 and a 1 year high of $31.01. The stock’s 50-day moving average is $19.37 and its 200-day moving average is $19.60. The firm has a market capitalization of $82.65 million, a price-to-earnings ratio of -1.16 and a beta of 2.18.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.